A Treatment Protocol to Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Trial Profile

A Treatment Protocol to Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 24 May 2017

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Expanded access
  • Sponsors Genentech; InterMune
  • Most Recent Events

    • 24 May 2017 Pooled long-term results from two real-world studies (NCT02699879 and NCT02141087) presented at the Digestive Disease Week 2017
    • 24 May 2017 Safety findings from pooled trial databases (NCT00662038, NCT02699879 and NCT02141087); resultpresented at the 113th International Conference of the American Thoracic Society
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top